Menu
Recruiting NCT06785324

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

No phase Interventional Philadelphia Chromosome Negative B Cell Acute Lymphoblastic Leukemia (B-ALL) B-ALL

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Nutrition Intervention, Exercise intervention.
Who it may be relevant to
Registry conditions: Philadelphia Chromosome Negative, B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL. Basic parameters: 18 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Nutrition and Exercise to Optimize Muscle and Adiposity in Adults With ALL: NEOMA ALL Trial

Overview

This clinical trial aims to assess the effect of nutrition and exercise on muscle and adiposity in adults with Philadelphia Chromosome (Ph) Negative B-ALL undergoing inpatient induction therapy. Participants will take part in 2 different interventions: * Nutrition Intervention * Physical Exercise Intervention All subjects will be provided with a wearable electronic activity monitor (FitBit®) to assist in recording activity levels in minutes of activity.

Interventions

  • Behavioral Nutrition Intervention
    The nutrition intervention will target a 10% caloric deficit calculated from each patient's Basal Metabolic Rate (WHO/Schofield) utilizing a high protein (\>25%), low fat (\<25%), low glycemic index/high fiber (45-55%) diet. The study registered dietician (RD) will meet with the patient on day of enrollment to go over the "menu" of dietary options and will re-assess the patient every two days (excluding weekends) for adherence. My Plate (USDA) will control portion size and eating habits.
  • Behavioral Exercise intervention
    The exercise intervention will target 200 minutes of "moderate" physical activity weekly, as defined by Metabolic Equivalents (METs) of 3-6, made up of aerobic and resistance training activities tailored to the patient's preference by working with the study physical therapist (PT). Physical Therapist to evaluate patient every 48 hours, excluding weekends.

Primary outcome measures

  • Feasibility of nutrition and exercise intervention [Time frame: End of study recruitment (approximately 1 year)]
Secondary outcome measures (8)
  • Adherence to dietary intervention [Time frame: 22 days]
  • Adherence to exercise intervention [Time frame: 22 days]
  • Usability of interventions [Time frame: 22 days]
  • Body composition changes - Visceral Adiposity [Time frame: 22 days]
  • Body composition changes - Sarcopenia (SMI) [Time frame: 22 days]
  • Impact on minimal residual disease (MRD) [Time frame: 22 days]
  • Impact on Treatment toxicities [Time frame: 22 days]
  • Changes to the Host Metabolome [Time frame: 22 days]

Eligibility criteria

Inclusion criteria

  • New Diagnosis of Philadelphia Chromosome Negative B-ALL
  • Receiving intensive pediatric-inspired induction chemotherapy

Exclusion criteria

  • BMI ≤18.5 kg/m2 at time of diagnosis
  • Unable to comply with both the recommended diet and exercise regimen as deemed by the research or treatment team
  • Pregnant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • University of Chicago Medicine Comprehensive Cancer Center — Chicago

Identifiers

NCT: NCT06785324 · IRB24-1500

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗